SCHEDULE: ARK Investment Management Discloses 9.19% Stake in Arcturus

ARK Investment Management LLC and Catherine D. Wood filed an Amendment No. 9 on Schedule 13G, disclosing a 9.19% beneficial ownership in Arcturus Therapeutics Holdings Inc.

Summary

• ARK Investment Management LLC and Catherine D. Wood jointly filed an Amendment No. 9 on Schedule 13G.
• The filing discloses beneficial ownership of 2,611,099 shares of Common Stock in Arcturus Therapeutics Holdings Inc.
• This represents 9.19% of the class of securities.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• ARK Investment Management LLC holds sole voting and dispositive power over 2,611,099 shares.
• Catherine D. Wood holds shared voting and dispositive power over 2,611,099 shares.
• ARK Genomic Revolution ETF, a series of a Delaware statutory trust, is noted as a client of ARK Investment Management LLC with an interest in the securities exceeding 5 percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of passive ownership and does not contain new financial performance data or strategic updates from the company itself.

Future Outlook

NA

Management Comments

• Kellen Carter, Chief Compliance Officer of ARK Investment Management LLC, certified the information.
• Catherine D. Wood, Chief Executive Officer and Chief Investment Officer, certified the information.

Industry Context

StockSavvy.ai notes that ARK Investment Management, led by Catherine D. Wood, is a prominent investment firm known for its focus on disruptive innovation, particularly in sectors like biotechnology and genomics. Their continued significant stake in Arcturus Therapeutics Holdings Inc. signals their ongoing conviction in the company's potential within the biotech space, aligning with ARK's broader investment themes.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a prominent investment firm like ARK Investment Management may positively influence investor sentiment and perception of Arcturus Therapeutics Holdings Inc., potentially signaling confidence in the company's long-term prospects.

Key Dates

Keywords

ARK Investment Management, Catherine D. Wood, Arcturus Therapeutics Holdings Inc., Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology, ARK Genomic Revolution ETF